Matthias V. Kopp

Matthias V. Kopp publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Matthias V. Kopp sits on this spectrum.

Matthias V. Kopp D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Matthias V. Kopp sits on this spectrum.

Best Publications

• What is precision medicine

  Inke R. König;Oliver Fuchs;Oliver Fuchs;Gesine Hansen;Erika von Mutius

  553
  Citations

• Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases

  Oliver Pfaar;Claus Bachert;Albrecht Bufe;Roland Buhl

  424
  Citations

• The impact of probiotics and prebiotics on the immune system

  Todd R. Klaenhammer;Michiel Kleerebezem;Matthias Volkmar Kopp;Maria Rescigno

  380
  Citations

• Preterm birth and sustained inflammation: consequences for the neonate.

  Unknown

  266
  Citations

• Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma

  M. V. Kopp;E. Hamelmann;S. Zielen;W. Kamin

  230
  Citations

• Polymorphisms in the IL 18 gene are associated with specific sensitization to common allergens and allergic rhinitis.

  Susanne Kruse;Joachim Kuehr;Michael Moseler;Matthias V. Kopp

  186
  Citations

• Critical link between TRAIL and CCL20 for the activation of TH2 cells and the expression of allergic airway disease

  Markus Weckmann;Adam Collison;Jodie L Simpson;Matthias V Kopp

  174
  Citations

• A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen.

  C. Rolinck-Werninghaus;H. Wolf;C. Liebke;J. C. Baars

  167
  Citations

• Perspectives on allergen-specific immunotherapy in childhood: an EAACI position statement.

  M A Calderon;R Gerth van Wijk;I Eichler;P M Matricardi

  136
  Citations

• Guideline (S2k) on acute therapy and management of anaphylaxis: 2021 update

  Johannes Ring;Kirsten Beyer;Tilo Biedermann;Andreas Bircher

  136
  Citations

• Lack of detectable alterations in immune responses during sublingual immunotherapy in children with seasonal allergic rhinoconjunctivitis to grass pollen.

  C. Rolinck-Werninghaus;M. Kopp;C. Liebke;J. Lange

  127
  Citations

• Perspectives in allergen immunotherapy: 2019 and beyond

  Oliver Pfaar;Ioana Agache;Frédéric de Blay;Sergio Bonini

  121
  Citations

• The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis.

  Matthias Volkmar Kopp;Jens Brauburger;Frank Riedinger;Dorothee Beischer a

  115
  Citations

• Guideline on allergen immunotherapy in IgE-mediated allergic diseases

  Unknown

  111
  Citations

• Association of TNF-α with severe respiratory syncytial virus infection and bronchial asthma

  Beena Puthothu;Sibylle Bierbaum;Matthias V. Kopp;Johannes Forster

  107
  Citations

• T2-high asthma phenotypes across lifespan

  Unknown

  102
  Citations

• Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy.

  Matthias Volkmar Kopp;Eckard Hamelmann;Meike Bendiks;Stefan Zielen

  98
  Citations

• ARIA guideline 2019: treatment of allergic rhinitis in the German health system.

  Ludger Klimek;Claus Bachert;Oliver Pfaar;Sven Becker

  97
  Citations

• Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial.

  Matthias Griese;Matthias Kappler;Claudia Eismann;Manfred Ballmann

  96
  Citations

• Perspectives in allergen immunotherapy: 2017 and beyond.

  O. Pfaar;S. Bonini;S. Bonini;V. Cardona;P. Demoly

  90
  Citations